PS100BTCL: Interest of the S100B Protein Assay in Mild Traumatic Brain Injuries at the DOUAI Hospital

Sponsor
Centre Hospitalier de Douai (Other)
Overall Status
Recruiting
CT.gov ID
NCT05285774
Collaborator
(none)
215
1
17.9
12

Study Details

Study Description

Brief Summary

The main objective is to evaluate the feasibility and interest of setting up a protocol for the systematic measurement of the S100B protein in patients with mild traumatic brain injury admitted to the emergency room of Douai hospital in order to reduce the number of unnecessary brain scans. The main evaluation criterion is the percentage of patients admitted to the emergency department of Douai hospital for mild traumatic brain injury, whose protocol for the systematic measurement of the S100B protein would make it possible to avoid the realization of a brain scans for patients with a protein assay S100B ≤ 0.10 µg/L, carried out within 3h of the onset of MCT.

The systematic dosage of the S100B protein in the context of mild traumatic brain injury still does not appear in the recommendations for good practice in 2021. This study will contribute to the reflection on the use of the S100B protein in the development of new recommendations for good practice of mild traumatic brain injury support.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is an observational, prospective, monocentric study. This study concerns patients over 18 years of age treated in the emergency room of Douai hospital for mild traumatic brain injury treated within 3 hours following the head trauma according to the Jéle et al classification and who have no history of melanoma.

    After verification of the patient's eligibility criteria for participation in this study, information relating to the research in order to obtain their authorization to participate in the research.

    Once authorization has been obtained, an additional tube of blood is collected when drawing blood samples from the patient as part of their care.

    Data are collected and a brain scan performed during the treatment and this is used to fill in the research data collection sheet.

    The data used in this research come from the direct questioning of patients. They are recorded on a paper form or in a computerized medical record.

    When the patient has been included in the trial the relevant data obtained from the direct questioning are taken from the sources indicated above and are entered on a data collection sheet specifically designed for this research.

    The collection sheet will be placed in a dedicated tray and will be collected each week from the emergency room.The data will be compiled in EXCEL ® software secured by a password. This file is hosted on the Douai hospital center server with restricted access.

    The files are protected by a password containing 8 characters (uppercase letters, lowercase letters and numbers), known only to the investigator, the person collecting the data, the clinical research assistant in charge of the study and the biostatistician in charge of data analysis.

    To meet the main objective, the two-sided 95% confidence interval of the observed percentage of patients admitted to the emergency room of the Douai hospital for mild traumatic brain injury with a brain scan classified as avoidable by the S100B protein assay protocol will be calculated by the exact Clopper-Pearson method.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    215 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    Interest in the Implementation of a Systematic Protocol for the Dosage of the S100B Protein in the Reduction of the Use of Brain Scans for Patients With Mild Traumatic Brain Injury in the Emergency Room of Douai Hospital
    Actual Study Start Date :
    Apr 6, 2022
    Anticipated Primary Completion Date :
    Apr 6, 2023
    Anticipated Study Completion Date :
    Oct 2, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Measurement of the S100B protein to the emergency department of the Douai hospital [At 3 hours after MCT]

      Percentage of patients admitted to the emergency department of the Douai hospital for MCT, whose protocol for the systematic measurement of the S100B protein would make it possible to avoid the realization of a brain scan for patients with a protein assay s100B ≤ 0.10 µg/L, carried out within 3h of the onset of MCT.

    Secondary Outcome Measures

    1. Measurement of the S100B protein for a threshold ≤0.10 µg//l [At 3 hours after MCT]

      Performance measures of the S100B protein for a threshold ≤0.10 µg//l: sensitivity, specificity, positive predictive value and negative predictive value.

    2. Length of hospital stay [Immediatly after the procedure]

      Evaluate the impact of adding this protocol to emergencies on the medical and paramedical team.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged over 18 years having had a traumatic brain within 3h with Glasgow >13

    • Patients having made a mild traumatic brain injury according to the Jehlé and Al classification:

    • Either, amnesia of the facts > 30 minutes before the MCT (retrograde amnesia) or either, loss of consciousness or amnesia associated with one of the following mechanisms :

    • Either pedestrian knocked down by a vehicle

    • Either patients ejected from a vehicle

    • Either fall from a height > 1 meter

    • Either Age > 65 years old

    • Either patients under anti platelet aggregation

    • Patients informed about the study

    Exclusion Criteria:
    • Patients with a history of melanoma or in melanoma follow-up care

    • Patients under guardianship or curatorship

    • Patients deprived of liberty (prisoner)

    • Patients not meeting MCT criteria

    • Refusal to participate in the study

    • Refusal to perform brain scan

    • Glasgow Rating <13

    • Unknown MCT Time

    • Unclear patient history

    • Polytraumatized

    • Congenital or acquired coagulopathy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre Hospitalier de Douai Douai Nord France 59507

    Sponsors and Collaborators

    • Centre Hospitalier de Douai

    Investigators

    • Principal Investigator: Justine HERENG, Centre Hospitalier de Douai

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Centre Hospitalier de Douai
    ClinicalTrials.gov Identifier:
    NCT05285774
    Other Study ID Numbers:
    • 01-2021-LJ3
    • IDRCB: 2021-A02163-38
    First Posted:
    Mar 18, 2022
    Last Update Posted:
    Apr 22, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Centre Hospitalier de Douai
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 22, 2022